Published in Mental Health Law Weekly, June 3rd, 2006
The purchase price is comprised of an initial payment and the potential for future payments linked to certain key milestones including FDA approval of the therapy and the establishment of reimbursement codes applicable to both the hospital and office settings. The former Solarant shareholders would also receive an earnout based on revenues achieved during the first 3 years in the event of product commercialization. In addition to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Mental Health Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.